Immunotherapy and non-small cell lung cancers

 

Authors

  • Letizia Laera UO Oncologia “Sandro Pitigliani”, Nuovo Ospedale di Prato “Santo Stefano”, Azienda USL Toscana Centro, Prato, Italy.
  • Silvia Novello AOU S. Luigi Gonzaga, Università degli Studi di Torino, Torino, Italy.

DOI:

https://doi.org/10.19156/cbn.2017.0052

Keywords:

lung cancer, immunotherapy, programmed cell death-1 (PD-1) inhibitors, programmed cell deathligand 1 (PD-L1) inhibitors

Abstract

Lung cancer is the leading cause of cancer mortality, and non-small cell lung cancer (NSCLC) accounts for more than 85% of all lung cancers. Immunotherapy has brought a paradigm shift to the treatment of NSCLC. Immune checkpoint inhibitors have emerged as one of the main new therapeutic options for patients with advanced NSCLC. This brief review focuses on analyzing the biological rationale and early clinical data available concerning immunotherapeutic strategies, and more specifically, programmed cell death-1 (PD-1) inhibitors and programmed cell death-ligand 1 (PD-L1) inhibitors.

Downloads

Published

2017-12-15

How to Cite

1.
Laera L, Novello S. Immunotherapy and non-small cell lung cancers:  . CBN [Internet]. 2017 Dec. 15 [cited 2024 Nov. 21];5(3):6-10. Available from: https://journals.aboutscience.eu/index.php/cancerbreakingnews/article/view/188

Issue

Vol. 5 No. 3 (2017): December 2017

Section

Review

License

Articles published in Cancer Breaking News are distributed under the CC Attribution-NonCommercial-NoDerivatives 4.0 license, which allows third parties to copy and redistribute the material providing appropriate credit and a link to the license but does not allow to use the material for commercial purposes and to use the material if it has been remixed, transformed or built upon.